Parameters of Calcium Metabolism Fluctuated during Initiation or Changing of Antipsychotic Drugs
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveaaSerum parameters of calcium homeostasis were measured based on previously published evidence linking osteoporotic fractures and/or bone/mineral loss with antipsychotics. MethodsaaProspective, four-week, time-series trial was conducted and study population consisted of patients of both genders, aged 35-85 years, admitted within the routine practice, with acute psychotic symptoms, to whom an antipsychotic drug was either introduced or substituted. Serial measurements of serum calcium, phosphorous, magnesium, 25(OH)D, parathyroid hormone, calcitonin, osteocalcin and C-telopeptide were made from patient venous blood samples. ResultsaaCalcium serum concentrations significantly decreased from baseline to the fourth week (2.42±0.12 vs. 2.33±0.16 mmol/L, p=0.022, n=25). The mean of all calcemia changes from the baseline was -2.6±5.7% (-24.1 to 7.7) with more decreases than increases (78 vs. 49, p=0.010) and more patents having negative sum of calcemia changes from baseline (n=28) than positive ones (n=10) (p=0.004). There were simultaneous falls of calcium and magnesium from baseline (63/15 vs. 23/26, p<0.001; OR=4.75, 95% CI 2.14–10.51), phosphorous (45/33 vs. 9/40, p<0.001; 6.06, 2.59–14.20) and 25(OH)D concentrations (57/21 vs. 13/35, p<0.001; 7.31, 3.25–16.42), respectively. Calcemia positively correlated with magnesemia, phosphatemia and 25(OH)D values. Parathyroid hormone and C-telopeptide showed only subtle oscillations of their absolute concentrations or changes from baseline; calcitonin and osteocalcin did not change. Adjustment of final calcemia trend (depletion/accumulation) for relevant risk factors, generally, did not change the results. ConclusionaaIn patients with psychotic disorders and several risks for bone metabolism disturbances antipsychotic treatment was associated with the decrease of calcemia and changes in levels of the associated ions.
Abstract
ObjectiveaaSerum parameters of calcium homeostasis were measured based on previously published evidence linking osteoporotic fractures and/or bone/mineral loss with antipsychotics. MethodsaaProspective, four-week, time-series trial was conducted and study population consisted of patients of both genders, aged 35-85 years, admitted within the routine practice, with acute psychotic symptoms, to whom an antipsychotic drug was either introduced or substituted. Serial measurements of serum calcium, phosphorous, magnesium, 25(OH)D, parathyroid hormone, calcitonin, osteocalcin and C-telopeptide were made from patient venous blood samples. ResultsaaCalcium serum concentrations significantly decreased from baseline to the fourth week (2.42±0.12 vs. 2.33±0.16 mmol/L, p=0.022, n=25). The mean of all calcemia changes from the baseline was -2.6±5.7% (-24.1 to 7.7) with more decreases than increases (78 vs. 49, p=0.010) and more patents having negative sum of calcemia changes from baseline (n=28) than positive ones (n=10) (p=0.004). There were simultaneous falls of calcium and magnesium from baseline (63/15 vs. 23/26, p<0.001; OR=4.75, 95% CI 2.14–10.51), phosphorous (45/33 vs. 9/40, p<0.001; 6.06, 2.59–14.20) and 25(OH)D concentrations (57/21 vs. 13/35, p<0.001; 7.31, 3.25–16.42), respectively. Calcemia positively correlated with magnesemia, phosphatemia and 25(OH)D values. Parathyroid hormone and C-telopeptide showed only subtle oscillations of their absolute concentrations or changes from baseline; calcitonin and osteocalcin did not change. Adjustment of final calcemia trend (depletion/accumulation) for relevant risk factors, generally, did not change the results. ConclusionaaIn patients with psychotic disorders and several risks for bone metabolism disturbances antipsychotic treatment was associated with the decrease of calcemia and changes in levels of the associated ions.
참고문헌 (48)
- Johnell O, "An estimate of the worldwide prevalence and disability associated with osteoporotic fractures", Osteoporos Int, 17, pp.1726~1733 (2006)
- Russell LA, "Osteoporosis and osteomalacia", Rheum Dis Clin North Am, 36, pp.665~680 (2010)
- Fong J, "Hypocalcemia : updates in diagnosis and management for primary care", Can Fam Physician, 58, pp.158~162 (2012)
- Liperoti R, "Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients : results of a case-control study", J Clin Psychiatry, 68, pp.929~934 (2007)
- Pouwels S, "Antipsychotic use and the risk of hip", femur fracture : a population-based case-control study, 2009, pp.20, 1499~1506
- Jalbert JJ, "Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia", J Am Med Dir Assoc, 11, pp.120~127 (2010)
- 이태영, "Bone Density in Chronic Schizophrenia with Long-Term Antipsychotic Treatment: Preliminary Study", PSYCHIATRY INVESTIGATION, 7(4), pp.278~284 (2010), 대한신경정신의학회
- Roke Y, "Bone mineral density in male adolescents with autism spectrum disorders and disruptive behavior disorder with or without antipsychotic treatment", Eur J Endocrinol, 167, pp.855~863 (2012)
- O’Keane V, "Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia", J Psychopharmacol, 22(2 Suppl), pp.70~75 (2008)
- Seriwatanachai D, "Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand", osteoprotegerin ratio, 2008, pp.42, 535~546
- Motyl KJ, "Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain", Bone, 50, pp.490~498 (2012)
- Sugawara N, "No association between bone mass and prolactin levels among patients with schizophrenia", Hum Psychopharmacol, 26, pp.596~601 (2011)
- Baastrup PC, "Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy", Neuropsychobiology, 6, pp.56~59 (1980)
- Nechifor M, "The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia", J Am Coll Nutr, 23, pp.549S~551S (2004)
- Wyszogrodzka-Kucharska A, "Calcium balance and regulation in schizophrenic patients treated with second generation antipsychotics", Psychiatr Pol, 39, pp.1157~1171 (2005)
- Zornic N, "Monitoring of drug-associated electrolyte disturbances in a hospital", Pharmacoepidemiol Drug Saf, 18, pp.1026~1033 (2009)
- Milovanovic DR, "Risperidone-associated hypocalcemia", Am J Psychiatry, 167, pp.1533~1534 (2010)
- Kishimoto T, "Osteoporosis and fracture risk in people with schizophrenia", Curr Opin Psychiatry, 25, pp.415~429 (2012)
- Douglas IJ, "Exposure to antipsychotics and risk of stroke: self controlled case series study", BMJ, 337, pp.a1227~ (2008)
- Keks NA, "Long-term management of people with psychotic disorders in the community", Aust Prescr, 30, pp.44~46 (2007)
- Morgan JL, "Rapidly assessing changes in bone mineral balance using natural stable calcium isotopes", Proc Natl Acad Sci U S A, 109, pp.9989~9994 (2012)
- James MT, "Derivation and internal validation of an equation for albumin-adjusted calcium", BMC Clin Pathol, 8, pp.12~ (2008)
- National Osteoporosis Foundation, "Clinician’s Guide to Prevention and Treatment of Osteoporosis", National Osteoporosis Foundation, ~ (2010)
- Taylor D, "The Maudsley Prescribing Guidelines in Psychiatry" (2012), Wiley Blackwell
- Benrimoj SI, "Efficacy and tolerability of the anti-inflammatory throat lozenge flurbiprofen 8.75 mg in the treatment of sore throat: a randomised, double-blind, placebo-controlled study", Clin Drug Invest, 21, pp.183~193 (2001)
- Favus MJ, "Cecil Medicine", pp.1871~1879 (2008), Saunders Elsevier
- Schoeber JP, "Concerted action of associated proteins in the regulation of TRPV5 and TRPV6", Biochem Soc Trans, 35(Pt 1), pp.115~119 (2007)
- Itzhaky D, "Low serum vitamin D concentrations in patients with schizophrenia", Isr Med Assoc J, 14, pp.88~92 (2012)
- Jamilian H, "Vitamin D, parathyroid hormone, serum calcium and phosphorus in patients with schizophrenia and major depression", Int J Psychiatry Clin Pract, 17, pp.30~34 (2013)
- Skouroliakou M, "Vitamin D insufficiency in obese patients with severe mental illness taking olanzapine", Med J Nutrition Metab, 5, pp.219~225 (2012)
- Henry HL, "Regulation of vitamin D metabolism", Best Pract Res Clin Endocrinol Metab, 25, pp.531~541 (2011)
- Daskalopoulos EP, "D₂-dopaminergic receptor-linked pathways: critical regulators of CYP3A, CYP2C, and CYP2D", Mol Pharmacol, 82, pp.668~678 (2012)
- Wojcikowski J, "Effect of classic and atypical neuroleptics on cytochrome P450 3A(CYP3A)in rat liver", Pharmacol Rep, 64, pp.1411~1418 (2012)
- Martin A, "Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis", Adv Exp Med Biol, 728, pp.65~83 (2012)
- Wu J, "Magnesium : the forgotten electrolyte", Aust Prescr, 30, pp.102~105 (2007)
- Liamis G, "A review of drug-induced hypocalcemia", J Bone Miner Metab, 27, pp.635~642 (2009)
- Liamis G, "Medication-induced hypophosphatemia : a review", QJM, 103, pp.449~459 (2010)
- Delva NJ, "Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia", Biol Psychiatry, 26, pp.781~793 (1989)
- Vetter T, "Magnesium and the parathyroid", Curr Opin Nephrol Hypertens, 11, pp.403~410 (2002)
- Higuchi T, "Certain neuroleptics reduce bone mineralization in schizophrenic patients", Neuropsychobiology, 18, pp.185~188 (1987)
- Sahota O, "Vitamin D insufficiency and the blunted PTH response in established osteoporosis : the role of magnesium deficiency", Osteoporos Int, 17, pp.1013~1021 (2006)
- Huang C, "Regulation of renal ion transport by the calcium-sensing receptor : an update", Curr Opin Nephrol Hypertens, 16, pp.437~443 (2007)
- Wu-Wong JR, "Mechanistic analysis for time-dependent effects of cinacalcet on serum calcium, phosphorus, and parathyroid hormone levels in 5", 6 nephrectomized rats, 2013, pp.1, e00046~
- Doknic M, "Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone", Neuroendocrinology, 94, pp.246~254 (2011)
- Labad J, "Stress biomarkers as predictors of transition to psychosis in at-risk mental states: roles for cortisol, prolactin and albumin", J Psychiatr Res, 60, pp.163~169 (2015)
- Vlahovic Z, "Healthcare in Serbia in transition period", EPMA J, 1, pp.601~606 (2010)
- Tugwell P, "Clinical Epidemiology - How to Do Clinical Practice Research", pp.356~387 (2006), Lippincot Williams & Wilkins
- Davis JM, "Dose response and dose equivalence of antipsychotics", J Clin Psychopharmacol, 24, pp.192~208 (2004)